Your fact-checks will appear here
The use of ivermectin in cancer treatment, specifically in a Phase I/II trial for metastatic triple-negative breast cancer, as of 2025.
Preclinical literature shows produces the most robust anticancer signals in (including triple‑negative), , , , (non‑small cell) and certain models, largely because it targets multiple survival and res...
Preclinical evidence places and its downstream Akt/mTOR axis as the single most consistently implicated route for —especially in where ivermectin promotes ubiquitin-mediated degradation of PAK1, reduc...
Preclinical literature shows repeated, drug‑level interactions between ivermectin and multiple chemotherapy or targeted agents—mostly beneficial pharmacodynamic synergies (enhanced tumor cell kill, re...
As of 2025, ClinicalTrials.gov shows a single registered interventional study testing ivermectin for cancer: a Phase I/II trial (NCT05318469) combining oral ivermectin with an immune checkpoint inhibi...